Clinical trial
An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
NCT03882034 is registered in ClinicalTrials.gov with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 21, 2019
- Completion date
- September 30, 2025
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pituitary disease